Your search returned 3 results.

Results
	1.	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. MedStar authors: Aroda, Vanita R PMID: 33468520 Year: 2021 Citation: Diabetes Care. 44(3):774-780, 2021 03. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Birkenfeld AL, Blonde L, Del Prato S, Frias J, Ji C, Niemoeller E, Rosenstock J, Souhami E DOI: https://dx.doi.org/10.2337/dc20-2023 Add to cart (remove)
	2.	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. MedStar authors: Weintraub, William S PMID: 31023428 Year: 2019 Citation: Journal of the American College of Cardiology. 73(16):2049-2058, 2019 04 30. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Berman DS, Boden WE, COURAGE Trial Research Group, Hartigan PM, Kostuk WJ, Mancini GBJ, Maron DJ, Spertus JA, Teo KK, Weintraub WS DOI: https://dx.doi.org/10.1016/j.jacc.2018.11.067 Add to cart (remove)
	3.	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors: Aroda, Vanita R PMID: 32139384 Year: 2020 Citation: Diabetes Care. 43(5):940-947, 2020 05. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N DOI: https://dx.doi.org/10.2337/dc19-1769 Add to cart (remove)

Powered by Koha